Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,106

Employees15,106

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,106

Employees15,106

REGN Key Statistics

Market cap

58.06B

Market cap58.06B

Price-Earnings ratio

13.94

Price-Earnings ratio13.94

Dividend yield

0.16%

Dividend yield0.16%

Average volume

1.58M

Average volume1.58M

High today

$552.84

High today$552.84

Low today

$535.77

Low today$535.77

Open price

$549.00

Open price$549.00

Volume

609.23K

Volume609.23K

52 Week high

$1,211.20

52 Week high$1,211.20

52 Week low

$520.50

52 Week low$520.50

REGN News

TipRanks 4d

Regeneron’s Promising Pipeline: Itepekimab’s Potential Impact on COPD Market and Stock Rating

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $958.00. Te...

Analyst ratings

73%

of 26 ratings

Buy

73.1%

Hold

19.2%

Sell

7.7%

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.